Ok then, Thanks tho, i didn't.
Ill leave this discussion alone,
Printable View
Check this out :
Director, Market Access and Reimbursement
Pacific Edge Diagnostics USA Ltd.
Hershey, PA
Responsible for the development and implementation of all market access strategies to secure and maintain access, coverage and reimbursement for all Pacific Edge Diagnostics products within the U.S.
• Developed and implemented all payer coverage strategies for Medicare, and Commercial payers which resulted in positive reimbursement for CxBladder.
• Collaborated with CMS to ensure appropriate implementation of access and pricing strategy regarding the new CMS proposed rule.
• Developed and submitted Federal Supply Schedule packet to secure access to CxBladder in VA/DOD as well as appropriate government pricing.
• Created and implemented field reimbursement strategies to support providers and internal stakeholders by removing reimbursement barriers and creating access to CxBladder.
• Collaborated with a cross-functional team of marketing, sales and medical affairs leaders to develop and implement tools to support commercial payers, Medicare, Medicaid and CMS, reimbursement initiatives.
• Effectively solicited, cultivated and established Key Opinion Leaders and CAC members, both regionally and nationally to support payer and reimbursement initiatives.
• Responsible for the over sight and implementation of pricing and contracting strategy for all key customer segments which resulted in increase access and reimbursement for CxBladder .
• Developed clinical payer scientific dossier to support coverage of CxBladder.
• Successfully developed and submitted to Medicare MAC the clinical value proposition, validation, and utility dossier for LCD reconsideration coverage inclusion of CxBladder.
• Developed and Implemented the Pacific Edge Patient Financial Assistance Program to ensure financial access to Cxbladder
Precisely!
Note the "Successfully developed and submitted to Medicare MAC the clinical value proposition, validation, and utility dossier for LCD reconsideration coverage inclusion of CxBladder."
Looks to me like PEB was rejected for LCD consideration 5 years ago! Was never mentioned once by DD or the company - it was all rah rah rah go go go, remember?
"Iterative" was the key word from past company advice.
Yup - that's PEB, same repetitive story just as this NBR headline :
https://www.nbr.co.nz/analysis/pacif...ss-or-oblivion
Clinical study supports adoption of Cxbladder
24/6/2019, 12:26 pmGENERALCLINICAL STUDY SUPPORTS ADOPTION OF CXBLADDER INTO NEW CLINCAL PATHWAY
Canterbury DHB publishes real-world clinical study with cementing evidence supporting the adoption of Cxbladder into the new clinical pathway
https://www.nzx.com/announcements/336487